Table Info

Table 1.

Molecular subtypes of breast cancers and treatment options outside of traditional surgery and radiotherapy [5–10]

Subtype	Molecular characteristics	Approximate incidence	Treatment options
Luminal A-like	ER⁺, PR^±, HER2^– Low Ki-67 Lower grade	60–70%	Endocrine therapy Targeted therapy Chemotherapy
Luminal B-like HER2^–	ER⁺, PR^±, HER2^– High Ki-67 Higher grade	10–20%	Endocrine therapy Targeted therapy Chemotherapy
Luminal B-like HER2⁺	ER⁺, PR^±, HER2⁺ High Ki-67 Higher grade	13–15%	Endocrine therapy Targeted therapy Chemotherapy
HER2-enriched (non-luminal)	ER^–, PR^–, HER2⁺ High Ki-67 Higher grade	13–15%	Chemotherapy Targeted therapy
Triple-negative	ER^–, PR^–, HER2^– High Ki-67 Higher grade	10–15%	Chemotherapy Targeted therapy Immunotherapy

Declarations

Author contributions

All authors contributed to the conception and design of the article, writing of the first draft of the manuscript, reading and approval of the submitted version. EYL and DCS revised the manuscript in response to reviewers comments.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Funding support was received from the Auckland Medical Research Foundation grant 1120013 (GJC); Cancer Society Auckland Northland (DCS); and Breast Cancer Foundation NZ grant R1902 (DCS, EYL). The funders had no role in the study design, in the collection, analysis, and interpretation of the data, in the writing of the report, or in the decision to submit the paper for publication.

Copyright

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. [DOI] [PubMed]

DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69:438–51. [DOI] [PubMed]

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. [DOI] [PubMed]

Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P. Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US from 2010 to 2016. JAMA Netw Open. 2020;3:e2013226. [DOI] [PubMed] [PMC]

Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5:77–106. [DOI] [PubMed] [PMC]

Lyons TG. Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol. 2019;20:82. [DOI] [PubMed]

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:66. [DOI] [PubMed]

Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5:2929–43. [PubMed] [PMC]

10.

Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108–14. [DOI] [PubMed]

11.

Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl). 2015;9:17–34. [DOI] [PubMed] [PMC]

12.

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al.; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21. [DOI] [PubMed]

13.

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al.; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21. [DOI] [PubMed]

14.

Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician. 2010;81:1339–46. [PubMed]

15.

Bland KI, Copeland EM, Klimberg VS, Gradishar WJ. The breast: comprehensive management of benign and malignant diseases. 5th ed. New York: Elsevier Inc; 2017.

16.

Schettini F, Buono G, Trivedi MV, De Placido S, Arpino G, Giuliano M. PI3K/mTOR inhibitors in the treatment of luminal breast cancer. Why, when and to whom? Breast Care (Basel). 2017;12:290–4. [DOI] [PubMed] [PMC]

17.

Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem. 2015;6:231–9. [DOI] [PubMed] [PMC]

18.

Ali S, Rasool M, Chaoudhry H, Pushparaj PN, Jha P, Hafiz A, et al. Molecular mechanisms and mode of tamoxifen resistance in breast cancer. Bioinformation. 2016;12:135–9. [DOI] [PubMed] [PMC]

19.

Hultsch S, Kankainen M, Paavolainen L, Kovanen RM, Ikonen E, Kangaspeska S, et al. Association of tamoxifen resistance and lipid reprogramming in breast cancer. BMC Cancer. 2018;18:850. [DOI] [PubMed] [PMC]

20.

Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol. 2001;97:855–66. [DOI] [PubMed]

21.

Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (review). Oncol Lett. 2015;9:1495–501. [DOI] [PubMed] [PMC]

22.

Jones ME, van Leeuwen FE, Hoogendoorn WE, Mourits MJ, Hollema H, van Boven H, et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res. 2012;14:R91. [DOI] [PubMed] [PMC]

23.

Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer. 2006;13:689–706. [DOI] [PubMed]

24.

Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90 Suppl 1:S2–6. [DOI] [PubMed] [PMC]

25.

Nawata H, Bronzert D, Lippman ME. Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. J Biol Chem. 1981;256:5016–21. [DOI] [PubMed]

26.

Daly RJ, Darbre PD. Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res. 1990;50:5868–75. [PubMed]

27.

Coser KR, Wittner BS, Rosenthal NF, Collins SC, Melas A, Smith SL, et al. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci U S A. 2009;106:14536–41. [DOI] [PubMed] [PMC]

28.

Lee AV, Oesterreich S, Davidson NE. MCF-7 cells—changing the course of breast cancer research and care for 45 years. J Natl Cancer Inst. 2015;107:djv073. [DOI] [PubMed]

29.

Leung E, Kannan N, Krissansen GW, Findlay MP, Baguley BC. MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther. 2010;9:717–24. [DOI] [PubMed]

30.

Baguley BC, Leung E. Heterogeneity of phenotype in breast cancer cell lines. In: Gunduz Mehmet, editor. Breast cancer–carcinogenesis, cell growth and signalling pathways. London: IntechOpen; 2011. pp. 245–56. [DOI]

31.

Leung E, Kim JE, Askarian-Amiri M, Finlay GJ, Baguley BC. Evidence for the existence of triple-negative variants in the MCF-7 breast cancer cell population. Biomed Res Int. 2014;2014:836769. [DOI] [PubMed] [PMC]

32.

Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther. 2011;11:938–46. [DOI] [PubMed] [PMC]

33.

Watanabe T, Oba T, Tanimoto K, Shibata T, Kamijo S, Ito KI. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer. PLoS One. 2021;16:e0252822. [DOI] [PubMed] [PMC]

34.

Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, et al. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res. 2008;68:8908–17. [DOI] [PubMed] [PMC]

35.

Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, et al. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. Int J Oncol. 2006;29:1237–46. [DOI] [PubMed]

36.

Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, Sørensen BS, Lykkesfeldt AE. T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. Cancer Lett. 2014;344:90–100. [DOI] [PubMed]

37.

Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol. 2003;17:309–17. [DOI] [PubMed]

38.

Yu S, Kim T, Yoo KH, Kang K. The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer. Biochem Biophys Res Commun. 2017;486:752–8. [DOI] [PubMed]

39.

Lim LY, Vidnovic N, Ellisen LW, Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer. 2009;101:1606–12. [DOI] [PubMed] [PMC]

40.

Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene. 2001;20:1465–75. [DOI] [PubMed]

41.

Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, et al. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. J Clin Invest. 2014;124:5490–502. [DOI] [PubMed] [PMC]

42.

Wong C, Chen S. The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance. J Steroid Biochem Mol Biol. 2012;131:83–92. [DOI] [PubMed] [PMC]

43.

Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, et al. Genomic profiling of ER⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017;9:eaai7993. Erratum in: Sci Transl Med. 2019;11:eaaw7620. [DOI] [PubMed] [PMC]

44.

Herzog SK, Fuqua SAW. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022;126:174–86. [DOI] [PubMed] [PMC]

45.

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015;7:313ra182. [DOI] [PMC]

46.

Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439–45. [DOI] [PubMed] [PMC]

47.

Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4:1116–30. [DOI] [PubMed] [PMC]

48.

Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446–51. [DOI] [PubMed] [PMC]

49.

Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, et al. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun. 2017;8:1865. [DOI] [PubMed] [PMC]

50.

Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, Lai CF, et al. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene. 2017;36:2286–96. [DOI] [PubMed] [PMC]

51.

Gonzalez TL, Hancock M, Sun S, Gersch CL, Larios JM, David W, et al. Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer. Breast Cancer Res Treat. 2020;180:611–22. Erratum in: Breast Cancer Res Treat. 2020;180:623. [DOI] [PubMed]

52.

Reynolds DS, Tevis KM, Blessing WA, Colson YL, Zaman MH, Grinstaff MW. Breast cancer spheroids reveal a differential cancer stem cell response to chemotherapeutic treatment. Sci Rep. 2017;7:10382. [DOI] [PubMed] [PMC]

53.

Singh M, Venkata Krishnan H, Ranganathan S, Kiesel B, Beumer JH, Sreekumar S, et al. Controlled three-dimensional tumor microenvironments recapitulate phenotypic features and differential drug response in early vs. advanced stage breast cancer. ACS Biomater Sci Eng. 2018;4:421–31. [DOI] [PubMed]

54.

Li J, Fang K, Choppavarapu L, Yang K, Yang Y, Wang J, et al. Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance. Clin Epigenetics. 2021;13:175. [DOI] [PubMed] [PMC]

55.

Lombardo Y, de Giorgio A, Coombes CR, Stebbing J, Castellano L. Mammosphere formation assay from human breast cancer tissues and cell lines. J Vis Exp. 2015;e52671. [DOI] [PubMed] [PMC]

56.

Kopp S, Sahana J, Islam T, Petersen AG, Bauer J, Corydon TJ, et al. The role of NFκB in spheroid formation of human breast cancer cells cultured on the Random Positioning Machine. Sci Rep. 2018;8:921. [DOI] [PubMed] [PMC]

57.

Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407–18. [DOI] [PubMed]

58.

Lo YH, Karlsson K, Kuo CJ. Applications of organoids for cancer biology and precision medicine. Nat Cancer. 2020;1:761–73. [DOI] [PubMed] [PMC]

59.

Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172:373–86.e10. [DOI] [PubMed]

60.

Sflomos G, Schipper K, Koorman T, Fitzpatrick A, Oesterreich S, Lee AV, et al. Atlas of lobular breast cancer models: challenges and strategic directions. Cancers (Basel). 2021;13:5396. [DOI] [PubMed] [PMC]

61.

Chen P, Zhang X, Ding R, Yang L, Lyu X, Zeng J, et al. Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer. Adv Sci (Weinh). 2021;8:e2101176. [DOI] [PubMed] [PMC]

62.

Signati L, Allevi R, Piccotti F, Albasini S, Villani L, Sevieri M, et al. Ultrastructural analysis of breast cancer patient-derived organoids. Cancer Cell Int. 2021;21:423. [DOI] [PubMed] [PMC]

63.

Dekkers JF, van Vliet EJ, Sachs N, Rosenbluth JM, Kopper O, Rebel HG, et al. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nat Protoc. 2021;16:1936–65. [DOI] [PubMed] [PMC]

64.

Ben-David U, Siranosian B, Ha G, Tang H, Oren Y, Hinohara K, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018;560:325–30. [DOI] [PubMed] [PMC]

65.

Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12:207–18. [DOI] [PubMed] [PMC]

66.

Nguyen-Ngoc KV, Cheung KJ, Brenot A, Shamir ER, Gray RS, Hines WC, et al. ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium. Proc Natl Acad Sci U S A. 2012;109:E2595–604. [DOI] [PubMed] [PMC]

67.

Bray LJ, Hutmacher DW, Bock N. Addressing patient specificity in the engineering of tumor models. Front Bioeng Biotechnol. 2019;7:217. [DOI] [PubMed] [PMC]

68.

Rosenbluth JM, Schackmann RCJ, Gray GK, Selfors LM, Li CM, Boedicker M, et al. Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages. Nat Commun. 2020;11:1711. [DOI] [PubMed] [PMC]

69.

Mollaki V. Ethical challenges in organoid use. BioTech. 2021;10:12. [DOI]

70.

Rossiter NJ, Huggler KS, Adelmann CH, Keys HR, Soens RW, Sabatini DM, et al. CRISPR screens in physiologic medium reveal conditionally essential genes in human cells. Cell Metab. 2021;33:1248–63.e9. [DOI] [PubMed] [PMC]

71.

Campaner E, Zannini A, Santorsola M, Bonazza D, Bottin C, Cancila V, et al. Breast cancer organoids model patient-specific response to drug treatment. Cancers (Basel). 2020;12:3869. [DOI] [PubMed] [PMC]

72.

Yip HYK, Papa A. Generation and functional characterization of murine mammary organoids. STAR Protoc. 2021;2:100765. [DOI] [PubMed] [PMC]

73.

Matthews SB, Sartorius CA. Steroid hormone receptor positive breast cancer patient-derived xenografts. Horm Cancer. 2017;8:4–15. [DOI] [PubMed] [PMC]

74.

Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell. 2016;167:260–74.e22. [DOI] [PubMed] [PMC]

75.

Sun Y, Yang N, Utama FE, Udhane SS, Zhang J, Peck AR, et al. NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers. Sci Adv. 2021;7:eabc8145. [DOI] [PubMed] [PMC]

76.

Castellaro AM, Rodriguez-Baili MC, Di Tada CE, Gil GA. Tumor-associated macrophages induce endocrine therapy resistance in ER⁺ breast cancer cells. Cancers (Basel). 2019;11:189. [DOI] [PubMed] [PMC]

77.

Dhimolea E, de Matos Simoes R, Kansara D, Weng X, Sharma S, Awate P, et al. Pleiotropic mechanisms drive endocrine resistance in the three-dimensional bone microenvironment. Cancer Res. 2021;81:371–83. [DOI] [PubMed] [PMC]

78.

Shiino S, Kinoshita T, Yoshida M, Jimbo K, Asaga S, Takayama S, et al. Prognostic impact of discordance in hormone receptor status between primary and recurrent sites in patients with recurrent breast cancer. Clin Breast Cancer. 2016;16:e133–40. [DOI] [PubMed]

79.

Zhu Y, Liu Y, Zhang C, Chu J, Wu Y, Li Y, et al. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. Nat Commun. 2018;9:1595. [DOI] [PubMed] [PMC]

80.

Alves CL, Ehmsen S, Terp MG, Portman N, Tuttolomondo M, Gammelgaard OL, et al. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. Nat Commun. 2021;12:5112. Erratum in: Nat Commun. 2021;12: 5588. [DOI] [PubMed] [PMC]

81.

Traphagen NA, Hosford SR, Jiang A, Marotti JD, Brauer BL, Demidenko E, et al. High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer. Oncogene. 2021;40:3408–21. [DOI] [PubMed] [PMC]

82.

Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995;80:2918–25. [DOI] [PubMed]

83.

Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst. 2001;93:1714–23. [DOI] [PubMed]

84.

Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst. 2003;95:1586–97. [DOI] [PubMed]

85.

Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005;97:1746–59. [DOI] [PubMed]

86.

Jordan VC. Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. J Natl Cancer Inst. 2014;106:dju296. [DOI] [PubMed] [PMC]

87.

Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011;1:338–51. [DOI] [PubMed] [PMC]

88.

Dittmer J. Nuclear mechanisms involved in endocrine resistance. Front Oncol. 2021;11:736597. [DOI] [PubMed] [PMC]

89.

Magnani L, Stoeck A, Zhang X, Lánczky A, Mirabella AC, Wang TL, et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A. 2013;110:E1490–9. [DOI] [PubMed] [PMC]

90.

Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, et al. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016;113:E6600–9. [DOI] [PubMed] [PMC]

91.

Simões BM, O’Brien CS, Eyre R, Silva A, Yu L, Sarmiento-Castro A, et al. Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity. Cell Rep. 2015;12:1968–77. [DOI] [PubMed] [PMC]

92.

Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, et al. Blockade of AP-1 potentiates endocrine therapy and overcomes resistance. Mol Cancer Res. 2016;14:470–81. [DOI] [PubMed] [PMC]

93.

Davies MP, Barraclough DL, Stewart C, Joyce KA, Eccles RM, Barraclough R, et al. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int J Cancer. 2008;123:85–8. [DOI] [PubMed]

94.

Morotti M, Bridges E, Valli A, Choudhry H, Sheldon H, Wigfield S, et al. Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proc Natl Acad Sci U S A. 2019;116:12452–61. [DOI] [PubMed] [PMC]

95.

Yang J, AlTahan A, Jones DT, Buffa FM, Bridges E, Interiano RB, et al. Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. Proc Natl Acad Sci U S A. 2015;112:15172–7. [DOI] [PubMed] [PMC]

96.

Leung EY, Askarian-Amiri ME, Singleton DC, Ferraro-Peyret C, Joseph WR, Finlay GJ, et al. Derivation of breast cancer cell lines under physiological (5%) oxygen concentrations. Front Oncol. 2018;8:425. [DOI] [PubMed] [PMC]

97.

Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, et al. ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol. 2012;10:e1001461. [DOI] [PubMed] [PMC]

98.

Takeiwa T, Ikeda K, Mitobe Y, Horie-Inoue K, Inoue S. Long noncoding RNAs involved in the endocrine therapy resistance of breast cancer. Cancers (Basel). 2020;12:1424. [DOI] [PubMed] [PMC]

99.

Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35:2746–55. [DOI] [PubMed] [PMC]

100.

Mitobe Y, Ikeda K, Suzuki T, Takagi K, Kawabata H, Horie-Inoue K, et al. ESR1-stabilizing long noncoding RNA TMPO-AS1 promotes hormone-refractory breast cancer progression. Mol Cell Biol. 2019;39:e00261–19. [DOI] [PubMed] [PMC]

101.

Shi YF, Lu H, Wang HB. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p. Eur Rev Med Pharmacol Sci. 2019;23:1563–73. [DOI] [PubMed]

102.

Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37:496–513. [DOI] [PubMed] [PMC]

103.

Ortega MA, Fraile-Martínez O, Asúnsolo Á, Buján J, García-Honduvilla N, Coca S. Signal transduction pathways in breast cancer: the important role of PI3K/Akt/mTOR. J Oncol. 2020;2020:9258396. [DOI] [PubMed] [PMC]

104.

Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35:515–24. [DOI] [PubMed]

105.

Xiao W, Zhang G, Chen B, Chen X, Wen L, Lai J, et al. Mutational landscape of PI3K-AKT-mTOR pathway in breast cancer: implications for targeted therapeutics. J Cancer. 2021;12:4408–17. [DOI] [PubMed] [PMC]

106.

Lee JJ, Loh K, Yap YS. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015;12:342–54. [DOI] [PubMed] [PMC]

107.

Xiao L, Wang YC, Li WS, Du Y. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res. 2009;28:152. [DOI] [PubMed] [PMC]

108.

Kwon HK, Bae GU, Yoon JW, Kim YK, Lee HY, Lee HW, et al. Constitutive activation of p70S6k in cancer cells. Arch Pharm Res. 2002;25:685–90. [DOI] [PubMed]

109.

Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al.; TCGA Research Network; Perou CM. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163:506–19. [DOI] [PubMed] [PMC]

110.

Anderson EJ, Mollon LE, Dean JL, Warholak TL, Aizer A, Platt EA, et al. A systematic review of the prevalence and diagnostic workup of PIK3CA mutations in HR⁺/HER2^– metastatic breast cancer. Int J Breast Cancer. 2020;2020:3759179. [DOI] [PubMed] [PMC]

111.

Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest. 2010;120:2406–13. [DOI] [PubMed] [PMC]

112.

Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 2011;13:R21. [DOI] [PubMed] [PMC]

113.

Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15:273–91. [DOI] [PubMed]

114.

Verret B, Cortes J, Bachelot T, Andre F, Arnedos M. Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol. 2019;30:x12–20. [DOI] [PubMed] [PMC]

115.

Markham A. Alpelisib: first global approval. Drugs. 2019;79:1249–53. [DOI] [PubMed]

116.

André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32:208–17. [DOI] [PubMed]

117.

Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, et al. A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov. 2017;7:102–13. Erratum in: Cancer Discov. 2018;8:1490. [DOI] [PubMed] [PMC]

118.

Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18:1360–72. Erratum in: Lancet Oncol. 2018;19:e667. [DOI] [PubMed] [PMC]

119.

Royce ME, Osman D. Everolimus in the treatment of metastatic breast cancer. Breast Cancer (Auckl). 2015;9:73–9. [DOI] [PubMed] [PMC]

120.

Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30:2718–24. [DOI] [PubMed]

121.

Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, et al. Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER⁺/HER2 mutant breast cancer. Clin Cancer Res. 2019;25:277–89. [DOI] [PubMed] [PMC]

122.

Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, et al. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res. 2012;14:R45. [DOI] [PubMed] [PMC]

123.

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al.; ASCENT Clinical Trial Investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–41. [DOI] [PubMed]

124.

Sikora MJ, Jacobsen BM, Levine K, Chen J, Davidson NE, Lee AV, et al. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Res. 2016;18:92. [DOI] [PubMed] [PMC]

125.

Lin X, Li J, Yin G, Zhao Q, Elias D, Lykkesfeldt AE, et al. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties. Breast Cancer Res. 2013;15:R119. [DOI] [PubMed] [PMC]

126.

Nguyen VT, Barozzi I, Faronato M, Lombardo Y, Steel JH, Patel N, et al. Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nat Commun. 2015;6:10044. Erratum in: Nat Commun. 2019;10:3505. [DOI] [PubMed] [PMC]

127.

Patten DK, Corleone G, Győrffy B, Perone Y, Slaven N, Barozzi I, et al. Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. Nat Med. 2018;24:1469–80. [DOI] [PubMed] [PMC]

128.

Marcotte R, Sayad A, Brown KR, Sanchez-Garcia F, Reimand J, Haider M, et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell. 2016;164:293–309. [DOI] [PubMed] [PMC]

129.

Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019;568:511–6. [DOI] [PubMed]

130.

Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, et al. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res. 2015;75:405–14. Erratum in: Cancer Res. 2019;79:876. [DOI] [PubMed]

131.

Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 2011;71:6773–84. [DOI] [PubMed] [PMC]

132.

Nagarajan S, Rao SV, Sutton J, Cheeseman D, Dunn S, Papachristou EK, et al. ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. Nat Genet. 2020;52:187–97. Erratum in: Nat Genet. 2020;52:354. [DOI] [PubMed] [PMC]

133.

Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nat Genet. 2020;52:198–207. [DOI] [PubMed] [PMC]

134.

Xiao T, Li W, Wang X, Xu H, Yang J, Wu Q, et al. Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. Proc Natl Acad Sci U S A. 2018;115:7869–78. [DOI] [PubMed] [PMC]

135.

Nguyen LV, Caldas C. Functional genomics approaches to improve pre-clinical drug screening and biomarker discovery. EMBO Mol Med. 2021;13:e13189. [DOI] [PubMed] [PMC]

136.

Georgopoulou D, Callari M, Rueda OM, Shea A, Martin A, Giovannetti A, et al.; IMAXT Consortium; Mills GB, Ali HR, Cosulich SS, Hannon GJ, Bruna A, Caldas C. Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nat Commun. 2021;12:1998. [DOI] [PubMed] [PMC]

137.

Wagner J, Rapsomaniki MA, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell. 2019;177:1330–45.e18. [DOI] [PubMed] [PMC]

138.

Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun. 2017;8:15081. [DOI] [PubMed] [PMC]

139.

Lim B, Lin Y, Navin N. Advancing cancer research and medicine with single-cell genomics. Cancer Cell. 2020;37:456–70. [DOI] [PubMed] [PMC]

140.

Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512:155–60. [DOI] [PubMed] [PMC]

141.

Grosselin K, Durand A, Marsolier J, Poitou A, Marangoni E, Nemati F, et al. High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer. Nat Genet. 2019;51:1060–6. [DOI] [PubMed]

142.

Lareau CA, Duarte FM, Chew JG, Kartha VK, Burkett ZD, Kohlway AS, et al. Droplet-based combinatorial indexing for massive-scale single-cell chromatin accessibility. Nat Biotechnol. 2019;37:916–24. [DOI] [PubMed]

143.

Nagasawa S, Kashima Y, Suzuki A, Suzuki Y. Single-cell and spatial analyses of cancer cells: toward elucidating the molecular mechanisms of clonal evolution and drug resistance acquisition. Inflamm Regen. 2021;41:22. [DOI] [PubMed] [PMC]

144.

Andersson A, Larsson L, Stenbeck L, Salmén F, Ehinger A, Wu SZ, et al. Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. Nat Commun. 2021;12:6012. [DOI] [PubMed] [PMC]